Annisa Jamil, MD
Glaucoma Specialist · Seattle, WANPI 1629006135
Payments from drug & device makers
Across 164 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$891
- Alcon$506
- Bausch & Lomb Americas Inc.$336
- Sun Pharmaceutical Industries Inc.$335
- Glaukos Corporation$196
- Rxsight Inc$189
- plus $824 from 15 others
What the payments were for
- Food & beverage$3,17597%
- Education$582%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $891 |
| Alcon | 18 | $506 |
| Bausch & Lomb Americas Inc. | 17 | $336 |
| Sun Pharmaceutical Industries Inc. | 16 | $335 |
| Glaukos Corporation | 7 | $196 |
| Rxsight Inc | 3 | $189 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $132 |
| Sight Sciences, Inc. | 6 | $107 |
| Thea Pharma Inc. | 5 | $94 |
| Aerie Pharmaceuticals, Inc. | 4 | $76 |
| Novartis | 4 | $76 |
| Dompe US, Inc. | 2 | $65 |
| Tarsus Pharmaceuticals, Inc. | 2 | $52 |
| Akorn, Inc. | 2 | $39 |
| Akorn Operating Company LLC | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Biotissue Holdings Inc. | 1 | $24 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $23 |
| Tearlab Corp | 1 | $20 |
| NEW World Medical,inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few glaucoma specialist providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 538 | $276,116 |
| RhopressaNetarsudil Mesylate | 338 | $180,269 |
| LumiganBimatoprost | 150 | $91,994 |
| RestasisCyclosporine | 71 | $61,543 |
| CombiganBrimonidine Tartrate/Timolol | 103 | $48,570 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 135 | $41,789 |
| RocklatanNetarsudil Mesylat/Latanoprost | 43 | $31,907 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 188 | $28,474 |
| Alphagan PBrimonidine Tartrate | 57 | $21,755 |
| MieboPerfluorohexyloctane/Pf | 22 | $18,993 |
| Difluprednate | 183 | $17,973 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 93 | $16,810 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 721 | $12,481 |
| Travoprost | 79 | $11,953 |
| TafluprostTafluprost/Pf | 55 | $11,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta, Miebo | $336 | $295,109560 claims |
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $891 | $223,863381 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $76 | $212,177381 claims |
| AlconSimbrinza, Azopt | $506 | $45,820146 claims |
| Akorn, Inc.Zioptan | $39 | $6,03712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Washingtonon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Seattle
- Jeffrey KennedySeattle$2K
- Shivali MendaSeattle$343
- Christian DraperSpokane$10K
- Travis FrazierPuyallup$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.